Work

High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.3_suppl.203

Authors: Ramya Thota, Timothy Yeatman, Nishant Gandhi, Mingli Yang, Michael Schell, Lance Pflieger, Andrey Loboda, Michael Nebozhyn, Andrew Elliott, Joanne Xiu, George W. Sledge, Moh'd M. Khushman, Emil Lou, Sanjay Goel, Warren Jack Pledger, Caris

Institutions: Intermountain Healthcare, University of South Florida, Caris Life Sciences (United States), Moffitt Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Washington University in St. Louis, University of Minnesota, Rutgers Cancer Institute, Tampa General Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4391091010

Cites:

Cited by:

Related to: 10